SCHEMBL10105923

SCHEMBL10105923

CCC(C)(C)c1ccc(OP)c(C(C)(C)CC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 6/20 0.55
NPSR1 Q6W5P4 5/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
ALDH1A1 P00352 1/20 0.55
MAPT P10636 5/20 0.50
HTT P42858 3/20 0.50
UBE2N P61088 2/20 0.50
GLA P06280 1/20 0.50
MITF O75030 1/20 0.50
RAB9A P51151 4/20 0.45
RAD52 P43351 2/20 0.45
STAT3 P40763 1/20 0.45
RCE1 Q9Y256 1/20 0.45
APAF1 O14727 1/20 0.45
HSP90AA1 P07900 1/20 0.45
NOD2 Q9HC29 1/20 0.45
NPC1 O15118 3/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8655138 0.87 MAPK1 (0.56) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL8473986 0.85 MAPK1 (0.57) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL988255 0.82 MAPK1 (0.55) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL8470405 0.82 MAPK1 (0.67) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL29443083 0.81 MAPK1 (0.54) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
Propane SCHEMBL10703212 0.81 MAPK1 (0.54) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL133717 0.81 MAPK1 (0.54) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL5145870 0.79 MAPK1 (0.61) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL6682777 0.79 MAPK1 (0.63) MAPK1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL8598929 0.79 MAPK1 (0.59) MAPK1NPSR1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8105668-B2 Crystalline form of 2-(4,6-bis-biphenyl-4-yl-1,3,5-triazin-2-yl)-5-(2-ethyl-(n)-hexyloxy)phenol BASF SE (DE) 2012-01-31 US disclosed
US-20110027509-A1 CRYSTALLINE FORM OF 2-(4,6-BIS-BIPHENYL-4-YL-1,3,5-TRIAZIN-2-YL)-5-(2-ETHYL-(N)-HEXYLOXY)PHENOL BASF SE (US) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110027509-A1 CRYSTALLINE FORM OF 2-(4,6-BIS-BIPHENYL-4-YL-1,3,5-TRIAZIN-2-YL)-5-(2-ETHYL-(N)-HEXYLOXY)PHENOL CRYZ, H1-4, H1-2 MAPK1 3227/4885NPSR1 3939/4885SMN1; SMN2 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.